Lv53
1408 积分 2024-09-19 加入
1959O BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)
19天前
已关闭
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
22天前
已完结
KRASG12C inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path
29天前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
29天前
已完结
Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee
1个月前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
1个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
1个月前
已完结
Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer
1个月前
已完结
Surgical approach matters for long-term lung cancer outcomes
1个月前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
1个月前
已完结
皖公网安备34019202002308
